Acs Dobfar Overview
- Year Founded
-
1973
- Status
-
Private
- Employees
-
1,065
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$170M
Acs Dobfar General Information
Description
Manufacturer of pharmaceutical products for the antibiotic sector intended to offer stakeholders cutting-edge anti-infective products. The company's products include beta-lactam and non-beta-lactam anti-infectives, cephalosporins, carbapenems and penicillins, enabling pharmaceutical companies to get cost-effective and affordable medicines.
Contact Information
Website
www.acsdobfar.itCorporate Office
- Viale Addetta, 4/12
- 20067 Tribiano(Milan)
- Italy
Corporate Office
- Viale Addetta, 4/12
- 20067 Tribiano(Milan)
- Italy
Acs Dobfar Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Debt - General | 15-Mar-2019 | $170M | Completed | Generating Revenue | ||
| 3. Debt Refinancing | 01-Sep-2016 | Completed | Generating Revenue | |||
| 2. Debt - General | 01-Jan-2014 | $82.3M | $135M | Completed | Generating Revenue | |
| 1. Debt - General | 01-Jan-2011 | $52.9M | $52.9M | Completed | Generating Revenue |
Acs Dobfar Patents
Acs Dobfar Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10214543-B2 | Synthesis of cephalosporin compounds | Active | 30-Dec-2014 | ||
| US-20180170949-A1 | Synthesis of cephalosporin compounds | Active | 30-Dec-2014 | ||
| US-20170129906-A1 | Reactions of thiadiazolyl-oximinoacetic acid derivative compounds | Active | 20-Jun-2014 | ||
| US-9695196-B2 | Reactions of thiadiazolyl-oximinoacetic acid derivative compounds | Active | 20-Jun-2014 | ||
| US-20160000921-A1 | Ceftolozane antibiotic compositions | Active | 15-Mar-2013 | A61K47/02 |
Acs Dobfar Signals
Acs Dobfar Acquisitions (2)
Acs Dobfar’s most recent deal was a Merger/Acquisition with Istituto Biochimico Italiano Giovanni Lorenzini. The deal was made on 22-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Istituto Biochimico Italiano Giovanni Lorenzini | 22-Jul-2026 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| GlaxoSmithKline (Antibiotic Production Business In Verona, Italy) | 01-Feb-2020 | Merger/Acquisition | Pharmaceuticals |
Acs Dobfar Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Ibigen - Societa A Responsabilita Limitata | Aprilia, Italy | 1980 | |
| La.Chi. Lavorazioni Chimiche | San Donato Milanese, Italy | 1977 | |
| Istituto Biochimico Italiano Giovanni Lorenzini | Aprilia, Italy | 1918 |
Acs Dobfar FAQs
-
When was Acs Dobfar founded?
Acs Dobfar was founded in 1973.
-
Where is Acs Dobfar headquartered?
Acs Dobfar is headquartered in Tribiano, Italy.
-
What is the size of Acs Dobfar?
Acs Dobfar has 1,065 total employees.
-
What industry is Acs Dobfar in?
Acs Dobfar’s primary industry is Pharmaceuticals.
-
Is Acs Dobfar a private or public company?
Acs Dobfar is a Private company.
-
What is Acs Dobfar’s current revenue?
The current revenue for Acs Dobfar is .
-
How much funding has Acs Dobfar raised over time?
Acs Dobfar has raised $501M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process